Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INGN
HoldSinkerInogen, Inc. · Healthcare · United States · $146M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Inogen designs, manufactures, and markets innovative portable oxygen concentrators (POCs) and accessories for patients with chronic respiratory conditions like COPD. Its competitive moat comes from patented technology delivering lightweight, compact, and long-lasting POCs, coupled with a strong brand and direct-to-consumer sales model. Inogen is a leader in portable oxygen therapy, enhancing patient mobility and independence through technological innovation.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 377.2M | 315.7M | 335.7M | 348.7M | -2.6% | 354.3M | 356.4M | 372.6M | 3.4% |
| EPS | -3.67 | -4.42 | -1.52 | -0.86 | — | -0.91 | — | — | — |
| Shares | 22.9M | 22.9M | 23.9M | 27.2M | +18.7% | 26.5M | — | — | — |
| Debt | 23.3M | 21.9M | 19.4M | 17.5M | -9.1% | 15.8M | — | — | — |
| Equity | 297.4M | 204.8M | 173.9M | 192.2M | -13.5% | — | — | — | — |
| Op CF | -37.5M | -3.2M | 5.9M | -11.2M | — | -2.5M | — | — | — |
| Inv CF | -10.9M | -59.3M | -14.0M | -26.2M | — | — | — | — | — |
| Fin CF | 0.4M | 1.0M | 0.3M | 24.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INGN | Inogen, Inc.(you) | $146M | 46 | Hold |
| RCEL | AVITA Medical, Inc. | $320M | 48 | Hold |
| MXCT | MaxCyte, Inc. | $126M | 32 | Sell |
| AOTI.L | AOTI, Inc. | $194M | 61 | Hold |
| SNWV | SANUWAVE Health, Inc. | $51M | 47 | Hold |
| TMCI | Treace Medical Concepts, Inc. | $302M | 39 | Hold |
| XTNT | Xtant Medical Holdings, Inc. | $54M | 44 | Hold |
| STIM | Neuronetics, Inc. | $224M | 33 | Sell |
| MASS | 908 Devices Inc. | $444M | 48 | Hold |
| LUNG | Pulmonx Corporation | $102M | 29 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%